Cancer Diagnostics Market Size, Share, Trends, Growth Outlook

Cancer Diagnostics Market is estimated to increase at a Compounded Annual Growth Rate of 8.9% CAGR over the forecast period from 2024 to 2030

The Cancer Diagnostics Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Product (Consumables, Instruments, Biopsy Instruments), By Technology (IVD Testing, Imaging, Biopsy Technique), By Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Others), By End-User (Hospitals, Diagnostic Laboratories).

An Introduction to Cancer Diagnostics Market in 2024

Cancer diagnostics encompasses a wide range of tests and procedures used to detect, diagnose, and characterize cancerous tumors and lesions in patients. In 2024, the field of cancer diagnostics continues to advance with innovations in imaging technology, molecular biomarkers, and liquid biopsy techniques aimed at improving early detection, treatment selection, and monitoring of cancer patients. From imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) to molecular tests including genomic profiling, circulating tumor DNA (ctDNA) analysis, and protein biomarker assays, cancer diagnostics offer a comprehensive approach to tumor detection and characterization. Moreover, with the integration of artificial intelligence and machine learning algorithms, diagnostic algorithms can provide automated interpretation of imaging studies, detection of subtle abnormalities, and prediction of treatment response, facilitating personalized treatment planning and precision oncology approaches. By enabling early detection, accurate diagnosis, and targeted therapy selection, cancer diagnostics play a crucial role in improving patient outcomes, reducing healthcare costs, and advancing cancer care in the era of precision medicine.

Market Trend: Advancements in Molecular Diagnostics and Precision Oncology

A significant trend in the cancer diagnostics market is the rapid advancements in molecular diagnostics and the emergence of precision oncology approaches for personalized cancer care. Molecular diagnostic technologies, such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and gene expression profiling, enable the analysis of genetic mutations, biomarkers, and molecular pathways associated with cancer development, progression, and response to treatment. Precision oncology aims to tailor cancer treatment strategies based on the unique molecular characteristics of individual tumors, allowing for more targeted therapies and improved patient outcomes. With ongoing research and technological innovations in genomics, proteomics, and bioinformatics, there is a growing emphasis on molecular profiling and precision medicine in cancer diagnosis, prognosis, and therapeutic decision-making, driving growth and innovation in the cancer diagnostics market.

Market Driver: Increasing Cancer Incidence and the Need for Early Detection

The primary driver fueling the growth of the cancer diagnostics market is the increasing incidence of cancer globally and the growing recognition of the importance of early detection and intervention. Cancer is one of the leading causes of morbidity and mortality worldwide, with millions of new cases diagnosed each year. Early detection of cancer is crucial for improving survival rates, enabling timely treatment initiation, and reducing the burden of advanced disease. Screening programs, diagnostic tests, and biomarker assays play a pivotal role in identifying cancer at an early stage when it is more treatable and curable. As healthcare organizations, governments, and advocacy groups prioritize cancer awareness, prevention, and screening initiatives, there is growing demand for innovative diagnostic technologies and strategies that enable early detection, accurate diagnosis, and personalized treatment planning, driving market growth in the cancer diagnostics sector.

Market Opportunity: Integration of Artificial Intelligence in Diagnostics Workflow

A potential opportunity for the cancer diagnostics market lies in the integration of artificial intelligence (AI) technologies to enhance diagnostic accuracy, efficiency, and workflow optimization. AI algorithms, including machine learning, deep learning, and natural language processing, offer capabilities for image analysis, data interpretation, and predictive modeling that can complement traditional diagnostic methods in cancer detection and diagnosis. AI-powered diagnostic tools can assist healthcare providers in interpreting medical imaging studies, identifying subtle abnormalities, and generating actionable insights from complex datasets. Furthermore, AI algorithms can help streamline diagnostic workflows, prioritize cases for review, and reduce turnaround times for test results, improving operational efficiency and patient care. By integrating AI into the cancer diagnostics workflow, manufacturers and healthcare providers can leverage the power of data-driven insights to support clinical decision-making, enhance patient outcomes, and drive innovation in cancer diagnosis and management.

Cancer Diagnostics Market Share Analysis: Next-generation Sequencing (NGS) is the fastest growing segment over the forecast period to 2030

Among the segments in the cancer diagnostics market, Next-generation Sequencing (NGS) emerges as the fastest-growing technology, owing to its revolutionary capabilities in identifying genetic mutations and alterations associated with various types of cancer. NGS enables comprehensive genomic profiling of tumor samples, allowing for the detection of a wide range of genetic abnormalities, including single nucleotide variations, insertions/deletions, gene fusions, and copy number alterations. This high-throughput sequencing technology offers unparalleled insights into the molecular landscape of cancer, facilitating personalized treatment strategies, prognostic assessments, and therapeutic decision-making. As the importance of genomic information in oncology continues to be recognized, coupled with ongoing advancements in NGS platforms, bioinformatics tools, and data analysis techniques, the adoption of NGS-based cancer diagnostics is rapidly expanding across hospitals and diagnostic laboratories worldwide, thus driving the significant growth observed in this segment of the cancer diagnostics market.

Cancer Diagnostics Competitive Analysis

The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAbbott Laboratories, F. Hoffmann-La Roche Ltd, GE Healthcare, QIAGEN N.V., Becton, Dickinson and Company, Koninklijke Philips N.V. , Siemens Healthcare GmbH, Hologic Inc, Thermo Fisher Scientific Inc, Illumina Inc

Cancer Diagnostics Market Segmentation

By Product
Consumables
Instruments
Biopsy Instruments
By Technology
IVD Testing
-Polymerase Chain Reaction (PCR)
-In Situ Hybridization (ISH)
-Immunohistochemistry (IHC)
-Next-generation Sequencing (NGS)
-Microarrays
-Flow Cytometry
-Immunoassays
-Others
Imaging
-Magnetic Resonance Imaging (MRI)
-Computed Tomography (CT)
- Positron Emission Tomography (PET)
-Mammography
-Ultrasound
Biopsy Technique
By Application
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Others
By End-User
Hospitals
Diagnostic Laboratories
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Cancer Diagnostics Market Companies

Abbott Laboratories
F. Hoffmann-La Roche Ltd
GE Healthcare
QIAGEN N.V.
Becton, Dickinson and Company
Koninklijke Philips N.V.
Siemens Healthcare GmbH
Hologic Inc
Thermo Fisher Scientific Inc
Illumina Inc

Reasons to Buy the Cancer Diagnostics Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Cancer Diagnostics Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Cancer Diagnostics Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Cancer Diagnostics Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Cancer Diagnostics Market Size Outlook, $ Million, 2021 to 2030
3.2 Cancer Diagnostics Market Outlook by Type, $ Million, 2021 to 2030
3.3 Cancer Diagnostics Market Outlook by Product, $ Million, 2021 to 2030
3.4 Cancer Diagnostics Market Outlook by Application, $ Million, 2021 to 2030
3.5 Cancer Diagnostics Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Cancer Diagnostics Industry
4.2 Key Market Trends in Cancer Diagnostics Industry
4.3 Potential Opportunities in Cancer Diagnostics Industry
4.4 Key Challenges in Cancer Diagnostics Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Cancer Diagnostics Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Cancer Diagnostics Market Outlook by Segments
7.1 Cancer Diagnostics Market Outlook by Segments, $ Million, 2021- 2030
By Product
Consumables
Instruments
Biopsy Instruments
By Technology
IVD Testing
-Polymerase Chain Reaction (PCR)
-In Situ Hybridization (ISH)
-Immunohistochemistry (IHC)
-Next-generation Sequencing (NGS)
-Microarrays
-Flow Cytometry
-Immunoassays
-Others
Imaging
-Magnetic Resonance Imaging (MRI)
-Computed Tomography (CT)
- Positron Emission Tomography (PET)
-Mammography
-Ultrasound
Biopsy Technique
By Application
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Others
By End-User
Hospitals
Diagnostic Laboratories

8 North America Cancer Diagnostics Market Analysis and Outlook To 2030
8.1 Introduction to North America Cancer Diagnostics Markets in 2024
8.2 North America Cancer Diagnostics Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Cancer Diagnostics Market size Outlook by Segments, 2021-2030
By Product
Consumables
Instruments
Biopsy Instruments
By Technology
IVD Testing
-Polymerase Chain Reaction (PCR)
-In Situ Hybridization (ISH)
-Immunohistochemistry (IHC)
-Next-generation Sequencing (NGS)
-Microarrays
-Flow Cytometry
-Immunoassays
-Others
Imaging
-Magnetic Resonance Imaging (MRI)
-Computed Tomography (CT)
- Positron Emission Tomography (PET)
-Mammography
-Ultrasound
Biopsy Technique
By Application
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Others
By End-User
Hospitals
Diagnostic Laboratories

9 Europe Cancer Diagnostics Market Analysis and Outlook To 2030
9.1 Introduction to Europe Cancer Diagnostics Markets in 2024
9.2 Europe Cancer Diagnostics Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Cancer Diagnostics Market Size Outlook by Segments, 2021-2030
By Product
Consumables
Instruments
Biopsy Instruments
By Technology
IVD Testing
-Polymerase Chain Reaction (PCR)
-In Situ Hybridization (ISH)
-Immunohistochemistry (IHC)
-Next-generation Sequencing (NGS)
-Microarrays
-Flow Cytometry
-Immunoassays
-Others
Imaging
-Magnetic Resonance Imaging (MRI)
-Computed Tomography (CT)
- Positron Emission Tomography (PET)
-Mammography
-Ultrasound
Biopsy Technique
By Application
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Others
By End-User
Hospitals
Diagnostic Laboratories

10 Asia Pacific Cancer Diagnostics Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Cancer Diagnostics Markets in 2024
10.2 Asia Pacific Cancer Diagnostics Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Cancer Diagnostics Market size Outlook by Segments, 2021-2030
By Product
Consumables
Instruments
Biopsy Instruments
By Technology
IVD Testing
-Polymerase Chain Reaction (PCR)
-In Situ Hybridization (ISH)
-Immunohistochemistry (IHC)
-Next-generation Sequencing (NGS)
-Microarrays
-Flow Cytometry
-Immunoassays
-Others
Imaging
-Magnetic Resonance Imaging (MRI)
-Computed Tomography (CT)
- Positron Emission Tomography (PET)
-Mammography
-Ultrasound
Biopsy Technique
By Application
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Others
By End-User
Hospitals
Diagnostic Laboratories

11 South America Cancer Diagnostics Market Analysis and Outlook To 2030
11.1 Introduction to South America Cancer Diagnostics Markets in 2024
11.2 South America Cancer Diagnostics Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Cancer Diagnostics Market size Outlook by Segments, 2021-2030
By Product
Consumables
Instruments
Biopsy Instruments
By Technology
IVD Testing
-Polymerase Chain Reaction (PCR)
-In Situ Hybridization (ISH)
-Immunohistochemistry (IHC)
-Next-generation Sequencing (NGS)
-Microarrays
-Flow Cytometry
-Immunoassays
-Others
Imaging
-Magnetic Resonance Imaging (MRI)
-Computed Tomography (CT)
- Positron Emission Tomography (PET)
-Mammography
-Ultrasound
Biopsy Technique
By Application
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Others
By End-User
Hospitals
Diagnostic Laboratories
12 Middle East and Africa Cancer Diagnostics Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Cancer Diagnostics Markets in 2024
12.2 Middle East and Africa Cancer Diagnostics Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Cancer Diagnostics Market size Outlook by Segments, 2021-2030
By Product
Consumables
Instruments
Biopsy Instruments
By Technology
IVD Testing
-Polymerase Chain Reaction (PCR)
-In Situ Hybridization (ISH)
-Immunohistochemistry (IHC)
-Next-generation Sequencing (NGS)
-Microarrays
-Flow Cytometry
-Immunoassays
-Others
Imaging
-Magnetic Resonance Imaging (MRI)
-Computed Tomography (CT)
- Positron Emission Tomography (PET)
-Mammography
-Ultrasound
Biopsy Technique
By Application
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Others
By End-User
Hospitals
Diagnostic Laboratories

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott Laboratories
F. Hoffmann-La Roche Ltd
GE Healthcare
QIAGEN N.V.
Becton, Dickinson and Company
Koninklijke Philips N.V.
Siemens Healthcare GmbH
Hologic Inc
Thermo Fisher Scientific Inc
Illumina Inc

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Product
Consumables
Instruments
Biopsy Instruments
By Technology
IVD Testing
-Polymerase Chain Reaction (PCR)
-In Situ Hybridization (ISH)
-Immunohistochemistry (IHC)
-Next-generation Sequencing (NGS)
-Microarrays
-Flow Cytometry
-Immunoassays
-Others
Imaging
-Magnetic Resonance Imaging (MRI)
-Computed Tomography (CT)
- Positron Emission Tomography (PET)
-Mammography
-Ultrasound
Biopsy Technique
By Application
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Others
By End-User
Hospitals
Diagnostic Laboratories
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)